弥漫大 B 细胞淋巴瘤（DLBCL）治疗面临挑战，部分患者预后差。CAR-T 疗法虽有进展，但在人群层面的生存改善不明。研究人员利用 SEER-17 数据库开展队列研究，发现 2018 - 2021 年确诊患者生存率提高。该研究为后续评估 CAR-T 疗效提供基准。

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Roche (RHHBY) announced that the European Commission, EC, has approved Columvi in combination with gemcitabine and oxaliplatin for the ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.